#ADCs

Akeso's Innovative Advances in Oncology: Phase II Trials for Novel ADCs Begin Akeso, Inc. has initiated Phase II trials for novel ADCs, advancing its "IO 2.0 + ADC 2.0" strategy by combining cutting-edge immunotherapy.

2 weeks ago

Akeso's Innovative Advances in Oncology: Phase II Trials for Novel ADCs Begin #China #Hong_Kong #Immunotherapy #ADCs #Akeso_Inc

0 0 0 0

Kelun-Biotech's 2025 Annual Results Showcase Successful Product Launches and Promising Future Kelun-Biotech's recent annual results reveal a successful year with multiple product launches and a strong development pipeline, solidifying its market position.

2 weeks ago

Kelun-Biotech's 2025 Annual Results Showcase Successful Product Launches and Promising Future #China #biopharmaceuticals #Chengdu #Kelun-Biotech #ADCs

0 0 0 0

Oncology Resource Group (ONCrg)

@onc-rg.bsky.social

2 weeks ago

📢 SGO 2026: The "Year of the ADC" is here.

The oncology landscape is moving fast, and the ONCrg team is headed to San Juan this April to catch every beat of the SGO 2026 Annual Meeting.

ONCrg Conference details: onc-rg.com/conferences/...
#SGO2026 #Oncology #ADCs #ClinicalTrials #EndoCancer #ONCrg

0 0 0 0

Antengene to Showcase Innovative Biotech Advancements at AACR 2026 Antengene Corporation Limited will reveal groundbreaking preclinical data on its dual-function T cell engagers at AACR 2026, focusing on ADCs.

3 weeks ago

Antengene to Showcase Innovative Biotech Advancements at AACR 2026 #United_States #San_Diego #Antengene #ADCs #TCEs

0 0 0 0

32-34 NEW PHARMA - In therapies PharmaTimes March explores today's life sciences landscape: patient autonomy where access to medicines is expected. Shifting politics, "super employees," ongoing innovation, GLP-1s, difficult-to-treat...

4 weeks ago

#obesity #diabetes #typeIIdiabetes #oncology #neurology #rarediseases #womenshealth #EliLilly #Akeso #SummitTherapeutics #precisionmedicine #immunotherapy #Alzheimersdisease #AstraZeneca #DaiichiSankyo #ADCs #precisiononcology #DrugstoWatch2026 #immunology #cardiology #CGTs
zurl.co/c8PJw

5 0 1 0

Pharma Fakten

@pharmafakten.bsky.social

1 month ago

Intelligentes Trio: Antikörper-Wirkstoff-Konjugate gegen Krebs ADCs sind einer der Innovationsmotoren in der Onkologie. Die Medikamente verändern das Leben von Menschen mit Krebs schon heute nachhaltig. Die Pipelines sind gut gefüllt.

#ADCs sind einer der Innovationsmotoren in der #Onkologie. Die #Medikamente verändern das Leben von Menschen mit #Krebs schon heute nachhaltig. Die #Pipelines sind gut gefüllt.

pharma-fakten.de/news/intelli...

0 0 0 0

Daiichi Sankyo gears up for five ADC launches in 2026

1 month ago

#DaiichiSankyo #ADCs #ADClaunches #Enhertu #Datroway #breastcancer #Oncology #antibodydrugconjugates #trastuzumabderuxtecan #datopotamabderuxtecan #pertuzumab #earlystagebreastcancer #triplenegativebreastcancer #Ifinatamabderuxtecan #IDXd #TROPIONBreast05study #ADCtechnology
zurl.co/TySHW

0 0 0 0

@oxfemale.bsky.social

1 month ago

THE ULTIMATE GUIDE TO WINDOWS COERCION TECHNIQUES IN 2025 Windows authentication coercion is still a powerful AD primitive: it forces predictable auth flows and enables relay chains. Modern mitigations reduce easy abuse, but when combined with AD CS o

Original text by redteampt

Windows authentication coercion remains a strong AD attack primitive because it enables deterministic forced authentication instead of relying on chance. #ActiveDirectory #ADCS #attacks #exploitation #windows
core-jmp.org/?p=249

0 0 0 0

Springer Medicine

@springermedicine.com

1 month ago

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy Bispecific antibody–drug conjugates represent a promising strategy to overcome the limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization.

Bispecific antibody–drug conjugates represent a promising strategy to overcome the limitations of conventional #ADCs in #BreastCancer, such as tumor heterogeneity and inefficient internalization.

Full story 👉 buff.ly/gQFqeyF

#OncSky

0 0 0 0

Nature Reviews Cancer

@natrevcancer.nature.com

1 month ago

Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment - Nature Reviews Cancer Antibody–drug conjugates are rapidly expanding both in the clinical treatment of cancer and in preclinical development. In this Review, Zippelius et al. highlight the molecular interactions and immune system effects of these sophisticated drugs that drive their efficacy and toxicity.

🥳And coming it at number 1🥁🥁🥁....
Our 1st most downloaded #REVIEW in 2025:

Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment

#ADCs #antibodydrugconjugates @NatResCancer
#NRCtop10of2025

3 1 0 0

Anthony J. Fontanez

@ajf8729.com

2 months ago

Four years running now, still managing to keep my lab root CA alive! I think the VM has been moved 3 or 4 times at this point, but I still keep managing to publish a new CRL! #PKI #ADCS

2 0 0 0

OncoDaily

@oncodaily.bsky.social

2 months ago

Abi Siva: ADCs are Now Listed as a 1L Option in mTNBC - OncoDaily Abi Siva: ADCs are Now Listed as a 1L Option in mTNBC / Abi Siva, ADCs, Breast Cancer, cancer, Dato-DXd, mTNBC, NCCN, OncoDaily, Oncology, Paolo Tarantino

ADCs are Now Listed as a 1L Option in mTNBC - Abi Siva

@abisivamd.bsky.social @ptarantinomd.bsky.social

oncodaily.com/voices/abi-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #mTNBC

1 0 0 0

OncoDaily

@oncodaily.bsky.social

2 months ago

MASCC Shares New Video on Managing Nausea and Vomiting in ADC Therapy - OncoDaily MASCC Shares New Video on Managing Nausea and Vomiting in ADC Therapy / cancer, Florian Scotte, Hope Rugo, Maryam Lustberg, MASCC, OncoDaily, Oncology

MASCC Shares New Video on Managing Nausea and Vomiting in ADC Therapy

@cancercaremascc.bsky.social

oncodaily.com/voices/mascc...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #ADCTherapy #ADCs #Nausea #Vomiting

3 0 0 0

OncoDaily

@oncodaily.bsky.social

2 months ago

Stephen V Liu: More on the Resistance to ADCs in the Journal of Thoracic Oncology - OncoDaily Stephen V Liu: More on the Resistance to ADCs in the Journal of Thoracic Oncology / Alissa Poteete, Ash A. Alizadeh, Ashwani Kumar, cancer, Caroline M.

More on the Resistance to ADCs in the Journal of Thoracic Oncology - Stephen V Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #ThoracicOncology #LungCancer #NSCLC

1 0 0 0

Consortium for Top-Down Proteomics

@proteoforms.bsky.social

2 months ago

NEW WORKSHOP "Top-Down, Intact, and Native Mass Spectrometry in Biopharmaceutical Characterization" Feb.12, 2026. Speakers from #AstraZeneca, #Novartis, #Pfizer, #Genentech, #Sanofi, #JnJ, #Lilly and #NIBRT share stories and perspectives. > ctdp.org/biopharma-wo... #ADCs #mAbs #BsAbs #TsAbs #AAVs

2 1 0 0

Antengene Showcases Groundbreaking Advances at JPM Conference: What's Next for ADCs and TCEs? Antengene Corporation Limited presents significant clinical data and strategic directions for next-generation ADCs and TCEs at the JPM Healthcare Conference, highlighting their future potential.

2 months ago

Antengene Showcases Groundbreaking Advances at JPM Conference: What's Next for ADCs and TCEs? #USA #San_Francisco #Antengene #ADCs #TCEs

0 0 0 0

Hasamba

@hasamba72.bsky.social

2 months ago

ADTrapper processes Windows AD auth logs with 54+ detection rules (brute force, password-spray, ADCS), accepts SharpHound collections, and offers force-directed graphs for relationship analysis. Containerized and anonymous uploads. #tool #ADTrapper #ADCS https://bit.ly/4jGMjUa

0 0 0 0

Unchained Labs Introduces Innovative ADC Characterization Tool for Researchers Unchained Labs enriches the research landscape with a new application that simplifies ADC characterization, enhancing the development process for researchers.

3 months ago

Unchained Labs Introduces Innovative ADC Characterization Tool for Researchers #USA #Pleasanton #ADCs #Unchained_Labs #Stunner

0 0 0 0

Closed & Collaborative H2 2025: Mergers, acquisitions, partnerships, collaborations, and strategic agreements The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

3 months ago

#RNA #ADCs #earlyphaseclinicalservices #biosimilars #marketentry #platformlicensing #Radiopharmaceuticals #hospitalAI #CDxpartnerships #genomicsequencing #biomarkerdiscovery #Digitalhealth #biologics #specialtymedicines #precisionmedicine #MandA #licensingagreements
zurl.co/ch3Xg

1 0 0 0

Proceedings Series MDPI

@proceedingsmdpi.bsky.social

3 months ago

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy
www.mdpi.com/2673-9992/40...

By Angel Justiz-Vaillant
From the 1st International Online Conference by Antibodies

#ADCs #AutoimmuneDiseases #TargetedTherapy #Immunotherapy

0 0 0 0

IT-Connect

@it-connect.bsky.social

3 months ago

🙏 Merci à nos contributeurs

En 2025, Hugues Moccand, a contribué avec l’écriture d’un cours IT :

📘 Maîtrisez l’Autorité de certification avec AD CS sous Windows Server
www.it-connect.fr/cours/ad-cs-...

#Windows #Certification #ADCS #ITConnect #Contributeurs #Merci

0 0 0 0

Aditya Basu

@adityabasu.bsky.social

3 months ago

🚨 New BioFlux Newsletter! Critical ADC safety hold on Daiichi Sankyo & Merck. Landmark approvals: Omeros' Yartemlea for TA-TMA & Edwards' SAPIEN M3 for mitral valve. Dive into biotech & health tech trends! Read now: #BioFlux #Biotech #HealthTech #ADCs #Nextechie

1 0 0 0

Allink Biotherapeutics Raises $47M to Propel Clinical Advancements and Innovative Drug Platforms Allink Biotherapeutics, Inc. has successfully completed $47 million extension rounds of Series A, accelerating its clinical development efforts for unique antibody-drug conjugates.

3 months ago

Allink Biotherapeutics Raises $47M to Propel Clinical Advancements and Innovative Drug Platforms #Shanghai #USA #oncology #Allink_Biotherapeutics #ADCs

1 0 0 0

Allink Biotherapeutics Secures $47 Million in Series A Funding to Propel Clinical Programs Forward Allink Biotherapeutics has successfully raised $47 million in additional Series A funding led by Legend Capital and Meituan Long-Z Investment, aiming to escalate their clinical programs.

3 months ago

Allink Biotherapeutics Secures $47 Million in Series A Funding to Propel Clinical Programs Forward #Shanghai #USA #oncology #Allink_Biotherapeutics #ADCs

1 0 0 0